An optimal vaccination rate among patients with IMID is important since these patients are at a higher risk for infectious diseases, according to Ms Liselotte Fierens (KU Leuven, Belgium) [1]. However, many patients do not achieve the guideline-recommended vaccination coverage. In a population of patients with IMID, only 27.4% had a full vaccination coverage in 2018. Ms Fierens and colleagues integrated a vaccination module in the electronic health record of the university hospital of Leuven to document and monitor the vaccination status of patients. Followed were 1,448 patients with IMID, of whom 798 were patients with inflammatory bowel diseases (IBD). The current vaccination status of these patients was compared with their vaccination status before the introduction of the vaccination tool in 2018.
In the whole study population, the vaccination coverage increased from 27.4% in 2018 to 51.9% in 2021 (P<0.001). In patients with IBD, the vaccination coverage increased from 42.2% to 60.4% (P<0.001). In addition, the proportion of specific vaccinations increased between 2018 and 2021 in patients with IBD, including influenza (75.9% vs 86.3%; P<0.001), pneumococci (72.9% vs 88.7%; P<0.001), hepatitis B (66.0% vs 80.2%; P<0.001), and tetanus (79.9% vs 85.7%; P=0.041). Ms Fierens concluded that this study demonstrated that the integration of a vaccination tool in the electronic health record of patients with IBD and other IMIDs improved the vaccination coverage in this at-risk population.
- Fierens L, et al. Implementation of a vaccination tool in the electronic patient health record significantly increased vaccination coverage. P115, ECCO 2022, 16–19 February.
Copyright ©2022 Medicom Medical Publishers
Posted on
Previous Article
« Comparable safety profiles of biological therapies in elderly patients with IBD Next Article
Novel classification system for perianal fistulising Crohn’s disease »
« Comparable safety profiles of biological therapies in elderly patients with IBD Next Article
Novel classification system for perianal fistulising Crohn’s disease »
Table of Contents: ECCO 2022
Featured articles
Upadacitinib maintenance therapy delivers sustained improvements in active ulcerative colitis
Novel Treatment Modalities
Guselkumab shows encouraging safety and efficacy in ulcerative colitis
Guselkumab maintenance therapy achieved high efficacy rates in Crohn’s disease
Mirikizumab efficacious for active ulcerative colitis
Risankizumab more efficacious in colonic than in ileal Crohn’s disease
Guselkumab plus golimumab promising combination for ulcerative colitis
Combined endpoint may support personalised medicine in ulcerative colitis
Filgotinib seems promising for perianal fistulising Crohn’s disease
Upadacitinib maintenance therapy delivers sustained improvements in active ulcerative colitis
Upadacitinib counters extraintestinal manifestations in ulcerative colitis
Deucravacitinib does not meet primary endpoint for ulcerative colitis
Head-to-Head Comparisons
Anti-TNFs versus vedolizumab and ustekinumab in Crohn’s disease
Upadacitinib appears to be an efficacious therapy for moderately-to-severely ulcerative colitis
Subcutaneous infliximab versus subcutaneous vedolizumab in IBD
Vedolizumab outperforms anti-TNF in biologic-naïve ulcerative colitis
Short-Term and Long-Term Treatment Results
Ozanimod treatment shows maintained response in ulcerative colitis
Stopping infliximab but not antimetabolites leads to more relapses in Crohn’s disease
Vedolizumab first approved therapy for chronic pouchitis
VEDOKIDS: Vedolizumab seems effective in paediatric IBD
Primary endpoint of 5-hydroxytryptophan for fatigue in IBD not met
Specific Therapeutic Strategies
Positive outcomes with therapeutic drug monitoring during infliximab maintenance therapy
Segmental colectomy beneficial over total colectomy in Chrohn’s disease
Modified 2-stage ileal pouch-anal anastomosis versus 3-stage alternative
Similar results for different corticosteroid tapering protocols in UC
Miscellaneous Topics
Lessons from the COVID-19 pandemic for IBD management
AI model distinguishes between histologic activity and remission in ulcerative colitis
Multi-Omic and dietary analysis of Crohn’s disease identifies pathogenetic factors
Novel classification system for perianal fistulising Crohn’s disease
Vaccination tool associated with improved vaccination coverage in IBD
Comparable safety profiles of biological therapies in elderly patients with IBD
Early biologic therapy induces larger effect than delayed treatment in Crohn’s disease
RESTORE-UC: No better outcomes with FMT superdonors than with autologous stools
Related Articles
September 28, 2021
Could steroid treatment speed recovery from infliximab-induced liver injury?
January 29, 2021
Cigarette smoke tied to colorectal neoplasia in IBD patients
December 1, 2022
Another chance for TYK2 inhibition in UC
© 2024 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy
HEAD OFFICE
Laarderhoogtweg 25
1101 EB Amsterdam
The Netherlands
T: +31 85 4012 560
E: publishers@medicom-publishers.com